Conference Coverage

Psoriatic arthritis treatment: “We’re not doing so well”

Publish date: March 7, 2018

 

EXPERT ANALYSIS FROM RWCS 2018

Pages

Recommended Reading

CV risk factors go undiagnosed, untreated in many psoriatic patients
Psoriatic Arthritis Resource Center
Get ready for certolizumab for psoriasis
Psoriatic Arthritis Resource Center
ACR sounds more welcoming tone in new biosimilars position paper
Psoriatic Arthritis Resource Center
Here comes bimekizumab, the newest IL-17 inhibitor
Psoriatic Arthritis Resource Center
Risankizumab outpaced ustekinumab for complete clearance of plaque psoriasis
Psoriatic Arthritis Resource Center
Experts review the year in rheumatology ... and what lies ahead
Psoriatic Arthritis Resource Center
Biologics have best chance of achieving PASI 90 in psoriasis
Psoriatic Arthritis Resource Center
Ustekinumab quells aortic inflammation in patients with severe psoriasis
Psoriatic Arthritis Resource Center
Could guselkumab be a disease-modifying agent in plaque psoriasis?
Psoriatic Arthritis Resource Center
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
Psoriatic Arthritis Resource Center